Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.021
Sell
RSI(14)
33.363
Neutral
STOCH(KDJ)(9,3,3)
30.192
Neutral
ATR(14)
0.038
High Vlolatility
CCI(14)
-99.607
Neutral
Williams %R
72.337
Sell
TRIX(12,20)
-0.694
Sell
StochRSI(14)
72.742
Buy
Search
Kairos Pharma Ltd
KAPAAdd to Watchlist
0.482USD
-0.010-2.05%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
10.32MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Kairos Pharma Ltd
Currency: USD Updated: 2026-05-15Key Insights
Kairos Pharma Ltd's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 170 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 9.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Kairos Pharma Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Kairos Pharma Ltd Highlights
StrengthsRisks
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company. It is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its lead candidate, ENV105, is an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. ENV105 focused on reversing drug resistance by targeting CD105 and restoring the effectiveness of standard therapies across multiple cancer types. ENV105 is in a Phase II clinical trial for castrate-resistant prostate cancer and a Phase I trial for lung cancer, with the trials aimed at addressing unmet medical needs. Its portfolio includes various drug therapies consisting of peptide and small molecule cancer immunotherapeutics KROS 101, 102, 201, 301, and 401 and therapeutic agents ENV 105 and 205.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Overvalued
The company’s latest PE is -1.64, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.15M shares, decreasing 49.36% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 0.00 shares of this stock.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
9.000
Target Price
+1839.66%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Kairos Pharma Ltd is 6.92, ranking 160 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
6.84
Operational Efficiency
4.00
Growth Potential
6.75
Shareholder Returns
7.03
Kairos Pharma Ltd's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Kairos Pharma Ltd is 5.76, ranking 353 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.64, which is -3.78% below the recent high of -1.57 and -917.69% above the recent low of -16.65.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 170/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Kairos Pharma Ltd is 8.00, ranking 161 out of 382 in the Biotechnology & Medical Research industry. The average price target is 9.00, with a high of 12.00 and a low of 4.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
9.000
Target Price
+1728.15%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Kairos Pharma Ltd
KAPA
3
CRISPR Therapeutics AG
CRSP
27
Beigene Ltd
ONC
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Kairos Pharma Ltd is 5.52, ranking 316 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.65 and the support level at 0.37, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
0.491
Sell
MA10
0.524
Sell
MA20
0.568
Sell
MA50
0.587
Sell
MA100
0.645
Sell
MA200
0.871
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Kairos Pharma Ltd. The Biotechnology & Medical Research industry's average is 3.36. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
--
VaR
--
240-Day Maximum Drawdown
+76.45%
240-Day Volatility
+149.70%
Return
Best Daily Return
60 days
+9.91%
120 days
+16.88%
5 years
--
Worst Daily Return
60 days
-12.15%
120 days
-12.15%
5 years
--
Sharpe Ratio
60 days
-0.80
120 days
-0.74
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+76.45%
3 years
--
5 years
--
Return-to-Drawdown Ratio
240 days
-0.24
3 years
--
5 years
--
Skewness
240 days
+3.61
3 years
--
5 years
--
Volatility
Realised Volatility
240 days
+149.70%
5 years
--
Standardised True Range
240 days
+17.84%
5 years
--
Downside Risk-Adjusted Return
120 days
-123.86%
240 days
-123.86%
Maximum Daily Upside Volatility
60 days
+62.56%
Maximum Daily Downside Volatility
60 days
+58.02%
Liquidity
Average Turnover Rate
60 days
+3.40%
120 days
+2.14%
5 years
--
Turnover Deviation
20 days
--
60 days
--
120 days
--
Peer Comparison
Biotechnology & Medical Research
Kairos Pharma Ltd
KAPA
5.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
